Based on the current week's news, the sentiment is positive for Sun Pharmaceutical Industries. Both news articles are recommending a "buy" rating with a target price of Rs 1870, indicating a bullish outlook.

Notable events mentioned in the news articles include Motilal Oswal's bullish stance on Sun Pharma, citing its growth potential and upside.

Historically, similar news articles have had a positive impact on the stock price, with an average impact of around 1.5%. This suggests that the news tone is positive for the stock.

Overall, the news tone is positive, indicating a potential upside for Sun Pharmaceutical Industries.